These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1878844)

  • 41. [Effects of maintenance treatment after high-dose intravenous gamma-globulin for idiopathic thrombocytopenic purpura].
    Yasunaga K; Kokawa T; Fujitake H; Nomura S; Kageyama T; Ohyabu H; Tatsumi N; Im T; Park K; Kawagoe H
    Rinsho Ketsueki; 1991 Sep; 32(9):938-44. PubMed ID: 1719256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapy of idiopathic thrombocytopenic purpura].
    Fiandino G; Messina M; Amerio M; Baldi P; Einaudi S; Saracco P
    Pediatr Med Chir; 1986; 8(1):33-7. PubMed ID: 3725611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous immunoglobulin.
    Consens Statement; 1990 May 21-23; 8(5):1-23. PubMed ID: 2263254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
    Durongpisitkul K; Gururaj VJ; Park JM; Martin CF
    Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous immunoglobulin therapy: magic or black magic.
    Barron KS; Sher MR; Silverman ED
    J Rheumatol Suppl; 1992 Apr; 33():94-7. PubMed ID: 1593608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IgG levels in Kawasaki disease and its association with clinical outcomes.
    Yamazaki-Nakashimada MA; Gámez-González LB; Murata C; Honda T; Yasukawa K; Hamada H
    Clin Rheumatol; 2019 Mar; 38(3):749-754. PubMed ID: 30343342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
    Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
    Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of intravenous immunoglobulin G in autoimmune hematologic disorders.
    Blanchette VS; Kirby MA; Turner C
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):72-82. PubMed ID: 1509297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A
    Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Old and current aspects of intravenous immunoglobulin therapy].
    Nydegger U
    Schweiz Med Wochenschr; 1994 Jan; 124(1-2):5-25. PubMed ID: 8296191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunoglobulin therapy].
    Ogata S; Ishii M
    Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
    Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
    Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.
    Downie ML; Manlhiot C; Latino GA; Collins TH; Chahal N; Yeung RS; McCrindle BW
    J Pediatr; 2016 Dec; 179():124-130.e1. PubMed ID: 27659027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
    Saulsbury FT
    Clin Pediatr (Phila); 2002 Oct; 41(8):597-601. PubMed ID: 12403377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
    Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease.
    JAMA; 1990 Dec; 264(24):3189-93. PubMed ID: 2255028
    [No Abstract]   [Full Text] [Related]  

  • 58. Multiple giant succular and fusiform right and left coronary artery aneurysms after early and adequate treatment of atypical kawasaki disease with unusual presentation.
    Behjati-Ardakani M; Ferdosian F
    Acta Med Iran; 2014; 52(6):490-2. PubMed ID: 25130161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of intravenous immunoglobulin in acquired immune deficiency syndrome.
    Yap PL; Todd AA; Williams PE; Hague RA; Mok J; Burns SM; Brettle RP
    Cancer; 1991 Sep; 68(6 Suppl):1440-50. PubMed ID: 1878843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
    Li X; Chen Y; Tang Y; Ding Y; Xu Q; Sun L; Qian W; Qian G; Qin L; Lv H
    Eur J Pediatr; 2018 Aug; 177(8):1279-1292. PubMed ID: 29948255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.